Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 7, 2012; 18(29): 3910-3916
Published online Aug 7, 2012. doi: 10.3748/wjg.v18.i29.3910
Table 1 Clinicopathologic characterization of patients with gastric adenocarcinoma treated by surgery in combination with chemotherapy
Normal serum CEA(median 52 yr, range: 22-74 yr)Elevated serum CEA(median 54 yr, range: 32-73 yr)
Datan (%)n (%)P
Sex0.090
Male116 (67.1)44 (80.0)
Female57 (32.9)11 (20.0)
Tumor location0.115
Upper52 (30.0)26 (47.3)
Middle42 (24.3)12 (21.8)
Lower68 (39.3)15 (27.3)
Total11 (6.4)2 (3.6)
Histological grade0.128
G11 (0.6)0 (0)
G231 (17.9)18 (32.7)
G3112 (64.7)29 (52.7)
G429 (16.8)8 (14.6)
Tumor size0.053
≤ 2 cm23 (13.3)1 (1.8)
2 cm < diameter ≤ 5 cm98 (56.6)36 (65.5)
> 5 cm52 (30.1)18 (32.7)
Boarrman type0.093
I3 (1.7)0 (0)
II90 (52.0)20 (36.4)
III69 (39.9)28 (50.9)
IV11 (6.4)7 (12.7)
Pathological T staging10.664
T06 (3.5)1 (1.8)
T3156 (90.2)49 (89.1)
T411 (6.4)5 (9.1)
Lymph node metastasis rate0.951
012 (6.9)3 (5.5)
0 < r ≤ 0.129 (16.8)8 (14.5)
0.1 < r ≤ 0.350 (28.9)17 (30.9)
r > 0.382 (47.4)27 (49.1)
Surgery0.313
Radical165 (95.4)50 (90.9)
Palliative8 (4.6)5 (9.1)
Chemotherapy0.384
Adjuvant130 (75.1)38 (69.1)
Perioperative43 (24.9)17 (30.9)